Examination No. 14-0231.1 Court File No. T-2030-13

FEDERAL COURT OF JUSTICE

BETWEEN:

NEIL ALLARD, TANYA BEEMISH, DAVID HERBERT, SHAWN DAVEY
PLAINTIFFS

- and - HER MAJESTY THE QUEEN IN RIGHT OF CANADA

DEFENDANT

CROSS-EXAMINATION OF TODD CAIN on his Affidavit Sworn on February 7, 2014 pursuant to an appointment made on consent of the parties to be reported by Catana Reporting Services, on February 20, 2014, commencing at the hour of 12:00 in the afternoon.

APPEARANCES:

John Conroy (via videoconference) for the Plaintiff

Jan Brongers) Kate Murton)

for the Defendant

ALSO PRESENT:

B.J. Wray Maria Molloy

This Examination was taken down by sound recording by Catana Reporting Services Ltd.

INDEX

NAME OF WITNESS: TODD CAIN

EXAMINATION BY: MR. CONROY

NUMBER OF PAGES: 56

ADVISEMENTS, OBJECTIONS & UNDERTAKINGS

NO EXHIBITS

DATE TRANSCRIPT ORDERED: February 28, 2014 DATE TRANSCRIPT COMPLETED: March 3, 2014

1

TODD CAIN, SWORN:

EXAMINATION BY: MR CONROY

Q. Mr. Cain, I have your Affidavit in front of me. As you indicate in paragraphs 3 and 4, your primary responsibilities and role in this matter was to try and ensure that everything is essentially in place by April 1st, 2014 as far as supply. Is that fair?

A. Yes.

Okay. So, I'm going to ask you -- I think 9 2. Ο. we'll just -- well, let's go through your Affidavit 10 quickly and then I've got some other things that I need 11 12 to update you on. In -- well, I take it you have not 13 been involved in -- as of paragraph 7 of your Affidavit talks about risks of public health, security and safety 14 and so on. That's just information you've been given 15 16 from others. You haven't been involved in that aspect of things at all. Your role again is simply to try and 17 18 ensure that there's enough licensed producers and enough supply available April 1st, 2014. Again, is that fair? 19

20 21

22

23

24

25

3.

1

2

3

4

5

6

7

8

1.

A. That is fair.

Q. Okay. At paragraph 8 you say that you're informed by Jacinthe David, Manager of Licensing and Permits Division of the Controlled Substances Office that the majority of the new licensed producers have availed themselves of this option. The option you're

talking about is their ability to have individuals sell 1 2 their seeds and plants, that's personal production 3 people, sell them to the licensed producers. When you say they've availed themselves of this option, are you 4 5 saying the licensed producers have, many of them 6 purchased plants and seeds from personal producers? 7 From personal producers and from designated Α. 8 persons as well. 9 4. Q. They have done so? That is correct. 10 Α. 5. Do you have any details or up to date 11 Q. information on what each of them has done in that 12 13 regard? 14 Α. So, I'm aware that more than half of 15 licensed producers to date have made at least one purchase ---16 17 MS. WRAY: I'm sorry, we're going to have to go 18 get our technical people. We're not able to hear the 19 answers at all. It's cutting in and out repeatedly. If 20 you just bare with us please? 21 MR. BRONGERS: Thank you. 22 (OFF RECORD DISCUSSION) 23 BY MR. CONROY: 24 6. At paragraph 24 of your Affidavit, Mr. Cain, 0. 25 set out a progress up to February 4, 2014. Can you

update us on that, please? 1 Certainly. The applications have continued 2 Α. 3 to come in. I did check before coming over this morning and the latest number is 491 applications have been 4 5 received, 131 are at the screening stage, 186 are in the 6 review stage, 79 have been returned as incomplete, 29 7 have the ready to build letter, 14 are pending the prelicense inspection, 5 are at final review, 9 have been 8 9 issued, 25 have been refused, and 13 have been 10 withdrawn. 11 7. Okay. So, we have nine that have been issued Q. 12 you said? That's correct. 13 Α. 14 8. Q. So on your next page, you indicate there 15 were six of the eight ready to register. So, you've listed six there. Please give me the name of the other 16 17 three. I don't know that I have the names of all 18 Α. three of the other companies that have been licensed. 19 20 9. Q. All right. Well let's do this then, you say 21 at paragraph 25 -- or 26 rather, that six of the eight are ready to resister clients. What's the situation with 22 23 respect to the nine? 24 So the delta between the two -- the Α. 25 difference between the two is, in one case the Prairie

CATANA REPORTING SERVICES. Tel: (613) 231-4664

Plant Systems is licensed to cultivate only and then 1 they have a corporate relationship with CanniMed. So 2 CanniMed is the legal entity, the company that will 3 actually register the patients, deal with the medical 4 5 records, et cetera. So that's the nature of that 6 relationship. The other two that are licensed but not 7 yet public are in a production phase. They've been licensed to start producing and their license will be 8 9 reviewed for a full licensure within the next few weeks 10 as they continue their construction and get ready for a final pre-license inspection. So ---11 They're not ready to register? 12 10. Q. That's right. They're in production but not 13 Α. 14 quite ready to register clients yet. 15 11. Q. Okay. So, are the six -- do we only have the six ready to register as indicated in paragraph 22? 16 17 Α. That is my understanding. 18 12. So nothing changed between February 14th, I Q. 19 think is the date of your Affidavit, and today on the 20 ready to register aspect of things? 21 A. Correct. 22 February 7th is your Affidavit. So over the 13. Q. 23 last three weeks we have no new licensed producers ready to register. Is that right? 24 25 Α. That is my understanding.

Q. Okay. All right, now in paragraph 27 you 14. 1 2 talk about the projected annual production capacity of the eight licensed. Are you able to produce 3 documentation for each of these to show exactly what 4 5 their current ability to produce is? 6 MR. BRONGERS: Mr. Conroy, this is a Cross-7 Examination on an Affidavit, we have no obligation to produce documents pursuant to it. So we will not be 8 9 undertaking to provide more material other than what is 10 already been attached to these affidavits. BY MR. CONROY: 11 12 15. Q. Do you have access then to documents from the companies that show exactly what their current 13 14 status is? 15 MR. BRONGERS: Mr. Conroy, what's the point of asking that question when I've just told you we are not 16 17 going to be providing any further paper. The affidavit 18 speaks for itself. BY MR. CONROY: 19 20 16. Q. All right. Well, the Affidavit does not --21 well, tell me this, what is the projected yield per 22 square foot of production space per month for Canna 23 Farms currently? 24 I don't know. Α. 25 17. Q. Do you know that for any of the six?

7

0

0

		A REPORTING SERVICE) 231-4664	ES, 800-170 Laurier Ave. W 1-800-893-6272	V., Ottawa,ON K1P 5V5 Fax: (613) 231-4605
1		A. No.		
2	18.	Q. How n	many square feet is buil	t out and in
3		production right	now for Canna Farms?	
4		A. I do	n't know.	
5	19.	Q. Do ye	ou know the answer to th	at question for
6		any of the other	licensed producers?	
7		A. I wo	uldn't I would know t	he approximate
8		number for two o	r three of the people th	at are licensed
9		to date.		
10	20.	Q. Who	are they?	
11		A. Peac	e Naturals and Tweed.	
12	21.	Q. I'm	told that Tweed has only	got 1,700
13		square feet buil	t out right now. Is that	correct?
14		A. That	is not my understanding	· •
15	22.	Q. What	is your understanding?	
16		A. That	they have over 10,000 s	quare feet built
17		out at this poin	t.	
18	23.	Q. That	's information they've s	upplied to you?
19		A. Corr	ect.	
20	24.	Q. I'm	told that Peace Naturals	currently only
21		has 3,000 square	feet built out right no	w. Is that
22		correct?		
23		A. That	is not my understanding	
24	25.	Q. What	is your understanding?	
25		A. Clos	er to 10,000 square feet	
14 15 16 17 18 19 20 21 22 23 24	23. 24.	A. That Q. What A. That out at this poin Q. That A. Corr Q. I'm has 3,000 square correct? A. That Q. What	is not my understanding is your understanding? they have over 10,000 s t. 's information they've s ect. told that Peace Naturals feet built out right no is not my understanding is your understanding?	oquare feet built upplied to you? currently only ow. Is that

CATANA REPORTING SERVICES. 800-170 Laurier Ave. W., Ottawa, ON K1P 5V5 Tel: (613) 231-4664 1-800-893-6272 Fax: (613) 231-4605 26. Again, information supplied by them to you? 1 Q. 2 Α. Correct. 27. 3 Q. Do you know the answer to the question for Bedrocan? 4 5 Α. Bedrocan is importing at this point. 6 28. So is Bedrocan going to be importing 100 Q. 7 kilograms per month or is it just the 100 kilograms that's been imported? 8 9 We are aware of a plan on their part to Α. 10 import over a couple of month period, over 100 kilos. 29. So when you say over 100 kilos, how much 11 Q. 12 over? 13 My understanding is the total will be in the Α. range of 130 to 140 kilos. 14 15 30. Q. Over two months you said? 16 A. Between now and May. 31. 17 Okay. Have any of the licensed producers Q. 18 managed to produce dry cannabis product to date? 19 Yes. Α. 20 32. Q. Which ones? The latest information I have is that there 21 Α. 22 is production at Tweed, Peace Naturals, Mettrum, Prairie 23 Plant Systems which as I indicated earlier is the 24 cultivation arm associated with CanniMed. Sorry, can you 25 just repeat the precise question, whether they have

produced ---1 33. 2 Q. Dry cannabis product to date? 3 A. So that would -- those are the ones that I am aware of that have finished product available. 4 5 34. Q. When you say available, have they passed the 6 microbiological for example? Let's take Mettrum as an 7 example. Has Mettrum passed its biological testing? A. As far as I'm aware, they are in compliance 8 9 with the regulations. 10 35. Well, my question's more specific. Have they Ο. -- has their product failed the tests or not at this 11 12 point? I don't know the results or their specific 13 Α. 14 testing. I know that they do have finished product in 15 inventory. 16 36. Q. But is it available for purchase by 17 consumers because it's completed all the tests? Or do 18 vou know? 19 I know that they have product available for Α. 20 sale. 21 37. Do you know how much? Q. 22 I don't have the precise numbers with me. Α. 23 38. Well, I need to know what is the -- how much Q. 24 dried cannabis product is available to date? 25 Α. So the last information I have is that

1		collectively, the licensed producers have just over 100
2		kilograms of finished dry marijuana in inventory
3		available for sale.
4	39.	Q. That's all of the licensed producers
5		combined?
6		A. Correct.
7	40.	Q. That's as of today's date?
8		A. That's the last information that I have and
9		I believe it is as of January 30th.
10	41.	Q. So that when you say 100 kilograms,
11		you're saying that so this is 100 kilograms that has
12		gone through all of the testing and procedures and
13		available for the consumer to purchase from them?
14		A. That's my understanding.
15	42.	Q. Okay. Are you able to say that they have
16		managed to produce in accordance with the projected
17		yield per square foot of production space per month to
18		date?
19		A. No, I'm not.
20	43.	Q. So you can't tell us of any variations
21		either then?
22		A. No.
23	44.	Q. Are you able to tell us how many of the
24		currently licensed LPs that have produced dried cannabis
25		product have tested that product to ensure that it

passes Health Canada's tolerance limits for heavy metals 1 2 and biologicals? A. I have no specific knowledge of the tests 3 that the product and inventory has undergone. All of 4 5 those licensed producers have demonstrated through the 6 licensing process the protocols, the testing procedures 7 to comply with the regulations. 45. Q. But you don't know if their product has 8 9 passed the tests? 10 I have not specifically verified that their Α. products have passed the tests. 11 Q. See I'm told that at least three of the 12 46. 13 eight have not even tested their product yet and that Mettrum's failed the tests. Is that correct? 14 15 Α. That is -- I have no knowledge of product having failed tests that is finished product in 16 17 inventory. I am aware that a number of these growers 18 have attempted to purchase marijuana from existing 19 growers and that some of that marijuana has failed the 20 tests under the new regulations. 21 47. Are you able to say how much? Q. 22 Α. No. 23 48. Any details? No details? Just that some of Q. 24 it has failed? 25 A. Yeah.

CATANA REPORTING SERVICES, Tel: (613) 231-4664

800-170 Laurier Ave. W., Ottawa,ON K1P 5V5 1-800-893-6272 Fax: (613) 231-4605

49. You can't tell us how much? 1 Q. 2 I couldn't qualify or quantify the Α. 3 percentages. That is information that is provided to me by the licensed producers themselves. 4 5 50. Q. But do we know how much then has been 6 purchased from personal producers or designated growers 7 on the issue you were speaking about in paragraph 8 of your Affidavit? Do we know how much of that -- what 8 9 volume has been purchased and is available through that 10 method? Well precise numbers, no. As I was starting 11 Α. 12 to answer, the majority of the producers, the new licensed producers have availed themselves of the option 13 14 of acquiring seeds or starting the materials in the form 15 of immature plants from existing growers. Those transactions of limited by the licenses of the 16 17 designated or personal grower. 18 51. I know, but I'm trying to get an idea of how Q. much volume that will be available by April 1st. 19 20 Α. Right. Well, as clear in the Affidavit based 21 on the production forecast of the licensed producers in 22 paragraph -- oh, sorry 29. That is what we expect they 23 will produce in April. What we are monitoring and don't 24 have an up to date number is what the level of inventory 25 will be between now and then. We do know that as of

January 30th, 100 kilos have been grown and placed into inventory and that the producers own forecast for April itself are for 850 kilos.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

16

52. Q. So you're not in a position to tell me how many of the currently licensed LPs that have produced dried cannabis product, have tested their dried cannabis product to ensure that it passes Health Canada's tolerance limits for heavy metals and biologicals. Is that correct?

Α. I have not personally verified their compliance with that aspect of the regulations.

53. Q. You can't tell me -- or tell us that of those LPs that have produced to date to what extent their product has passed or failed to pass Health 15 Canada's tolerance limits for heavy metals and biologicals?

17 A. I can tell you that a number of kilos have 18 been destroyed by the licensed producers based on their 19 information provided to us because they have not met 20 those testing standards. I don't remember the precise 21 number, but it would be in the single digits of 22 kilograms which have failed the testing protocols and 23 been destroyed.

24 54. Q. Are you able to give us a percentage 25 expressed as a current total of the built up production

1		space?
2		A. No.
3	55.	Q. So, is what I understand it, you take the
4		position, or say in your Affidavit that the LPs have a
5		proven 35,000 kilogram per year production capacity. Is
6		that correct?
7		A. That is the collective amount that they are
8		licensed to produce.
9	56.	Q. So it's not that they have a proven
10		capacity, they're just licensed to produce that. Is that
11		right?
12		A. As part of our licensing procedure we do
13		confirm that they have the testing protocols, the other
14		controls that are clear in the regulations including the
15		vault or storage capacity that lines up with the amount
16		of annual production in their license.
17	57.	Q. All right. So, you're not saying that that
18		exists right now, are you?
19		A. Not necessarily.
20	58.	Q. At paragraph 27 you discuss you say the
21		collective projected annual production capacity of the
22		eight is over 31,000 kilograms. Do you know how much
23		over?
24		A. Well it was rounded to 31,000 so it would
25		over would only be in the hundreds.

1	59.	Q. You predict that another 12 applicants will
2		be licensed to produce by March 31st. So I think you
3		said we're up to nine now. We've got 40 days to go. Is
4		that still your prediction?
5		A. Yes, it is.
6	60.	Q. Then you say these applicants projected
7		annual production capacities will increase to 31,000 to
8		45,000 kilograms, correct?
9		A. Correct.
10	61.	Q. But you're not saying that that product will
11		be available by March 31st, are you?
12		A. No.
13	62.	Q. So in the Affidavit have you had a chance
14		to look at the materials that were filed by the
15		Applicant?
16		A. Which materials?
17	63.	Q. Well for example, the Affidavit of Danielle
18		Lukiv?
19		A. No.
20	64.	Q. Okay. Did you know that a Freedom of
21		Information request was made back in July of 2013, and
22		it's attached as an Exhibit A to the Affidavit of
23		Danielle Lukiv, and the information provided was that,
24		"The total annual dried cannabis dosage or
25		consumption expressed in kilograms per year of

authorizations to possess licenses under the 1 MMAR with the dosage between 1 to 149 grams per 2 day." 3 But the total based on daily amount authorized was 4 5 188,189 kilograms as of April, 2013. Did you know that? 6 MR. BRONGERS: Mr. Conroy, we have Mr. Lukiv's 7 Affidavit with us. It might make it easier if you could point to the paragraph or Exhibit where that's stated. 8 9 MR. CONROY: Her Affidavit and it's Exhibit A. 10 MR. BRONGERS: Perhaps you could ask the question again, Mr. Conroy? What are you asking the 11 12 witness specifically? BY MR. CONROY: 13 65. Q. You'll see at Exhibit A, there's an Access 14 15 to Information Request filed July 19th, 2013 that asks the three questions that are posed there. The first one 16 17 being, 18 "The total annual dried cannabis dosage or consumption expressed in kilograms per year of 19 20 authorizations to possess licenses under the 21 MMAR with the dosage between 1 to 149 grams to day." 22 23 If you flip the page, the answer is set out at the top of the next page which is what I've read to you a little 24 25 earlier. Do you see that?

1		A. Yes.
2	66.	Q. My understanding is that is then the figure
3		of what how much marijuana was authorized to be
4		produced last year by all authorized to possess and
5		personal producers and designated growers. Is that
6		correct?
7		A. I have not seen these specific numbers
8		before but that number is generally familiar to me in
9		terms of the total authorized production under the old
10		regulations, yes.
11	67.	Q. So in other words, based on the various
12		patients and so on, that was the amount that was
13		produced for consumption by the patients last year,
14		correct?
15		A. That is the amount that was authorized.
16	68.	Q. Authorized pursuant to the specific
17		authorizations to possess and personal production
18		licenses and designated grow licenses that were in
19		effect last year?
20		A. Well as of the date when this document was
21		prepared, yes.
22	69.	Q. The second question was,
23		"The total number of authorizations to possess
24		licenses under the MMAR with the dosage of 150
25		grams or more per day?"

The answer on the next page appears to be 89 as of 1 April, 2013? 2 MR. BRONGERS: Mr. Conroy, are you asking him 3 just to confirm that's what the document says? 4 5 BY MR. CONROY: 6 70. Q. Did you know that or is this information 7 that has just come to your attention by reading the documents? 8 9 Α. I was aware of the number of authorizations 10 over 150 grams per day, yes. 11 71. Q. The next question set out there is, 12 "At the time of the repeal of licenses issued under the MMAR on March 31st, 2014 based on the 13 14 actual applications received by Health Canada as 15 well as the licenses Health Canada anticipates to issue for production of cannabis, the 16 17 anticipated total annual production capacity of 18 dried cannabis expressed in kilograms per year 19 of all anticipated licensed producers under the 20 MMPR estimated to be as of April 1st, 2014 21 provide us with your estimate in this regard on 22 a monthly basis commencing August, 2013 to March 23 2014." 24 The answer on the next page appears to be nil from BMC. 25 Do you know what that means?

That there were no documents that Α. 1 2 corresponded to the Access to Information Request would 3 be my understanding. 72. Q. BMC being the Bureau of Medical Cannabis? 4 5 A. Correct. 6 73. Q. Okay. So as of that date though, they 7 weren't able to estimate the production by April 1st, 2014. Is that fair? 8 9 A. That would be my understanding. 10 74. Q. If you go then to the next Exhibit, Exhibit 11 B, you'll see a further Access to Information Request, October 9th, 2013, that's ---12 MR. BRONGERS: Mr. Conroy, is there a page 13 14 number perhaps that you could reference for us? We don't 15 have tabs here. MR. CONROY: Oh you don't? Okay. Well, it's 16 17 immediately following the last one. 18 THE WITNESS: This is the correspondence with the Secretary of the International Narcotic Control 19 20 Board? 21 MR. CONROY: No, you should have -- before that there should be the October 9th, 2013 request -- or 22 23 response. 24 MR. BRONGERS: We've found that. Exhibit B, 25 October 9th, 2013 letter to Ron Marzel, yes.

1		BY MR. CONROY:
2	75.	Q. So you've got a series of questions there
3		that are broken down in relations to the grams per day.
4		"Total current annual dried cannabis dosage or
5		consumption for 2012 calendar year expressed in
6		kilograms per year of authorization to possess
7		licenses under the MMAR."
8		The first one is 1 to 5 grams and then 6 to 10 grams, 11
9		to 20 grams, 21 to 50, 51 to 100 and 101 to 150 grams.
10		Do you see those where the questions?
11		A. Yes.
12	76.	Q. Then if you go a couple of pages, you'll see
13		the answers.
14		MR. BRONGERS: Is it, Mr. Conroy, a page which
15		starts with A-2013-00583 bottom of the page has a number
16		one on it?
17		MR. CONROY: That's correct.
18		THE WITNESS: Okay.
19		MR. BRONGERS: Yes, we have it.
20		MR. CONROY: If you go then to the next page,
21		you'll see on that first page it's got 1, 2, 3 and
22		then over to the next page, B, C, and D.
23		MR. BRONGERS: We have a form B, annual
24		estimates.
25		MR. CONROY: Well do you have page two? Page one

you've indicated you have. There's page two to the 1 answer that has a little box at the bottom with a 2 3 diagram that sets out the kilograms authorized in east 4 category. MR. BRONGERS: It appears, Mr. Conroy that we 5 6 may have a wrong copy. I'm going to look on my IPad 7 where I also have your Affidavit. So if you could just bare with me, I'll see if I can find it? 8 9 MR. CONROY: All right. 10 MR. BRONGERS: Yes, we now have it on my IPad. BY MR. CONROY: 11 77. 12 Q. All right. So the diagram or the schematic 13 at the bottom of page two gives us the breakdown in 14 daily grams and the corresponding kilograms authorized 15 in each category, doesn't it? 16 Α. Yes. 17 78. The largest group appears to be in the Q. 18 category of 11 to 20 grams. Isn't that correct? 19 Α. Yes. 20 79. Q. The second largest is 6 to 10 grams, 21 correct? 22 A. Correct. 23 80. So the -- we know, I take it from these Q. 24 figures, that the grams per day being authorized by 25 physicians across the country, the greatest numbers fall

into those two categories. Fair enough? 1 2 Under the old program, yes. Α. 81. 3 Q. But I mean -- so we know that in the past under the MMAR or even up to date under the MMAR that in 4 5 2012 up to the -- for the year of 2012, those were the 6 types of authorizations that doctors were giving to 7 patients under the MMAR. Fair enough? Yes. 8 Α. 9 82. Q. That the total authorized there was 167,780.33 kilograms? 10 11 Α. Yes. 83. Fair enough? So that figure and the earlier 12 Q. 13 figure we looked at a moment ago, the 188,819 as of April, 2013, are those not figures that give us an idea 14 15 of how much cannabis is being consumed as medicine by patients in Canada during those years? 16 17 Those figures are authorizations. I'm not Α. 18 aware of any systematic study that would give us any 19 real insights into how much of that authorization was 20 actually being consumed for medical purposes. 21 84. Whether you have that information or not, Q. 22 that's what was authorized to be consumed, wasn't it? 23 Yes. Α. 24 85. That was the demand made in terms of what Ο. 25 quantity was required to fulfil what was authorized.

Fair enough? 1 2 That's what was authorized. Α. 86. 3 Q. Yeah, on the basis of requests by patients authorized by their physicians, correct? 4 5 Α. The authorizations to possess yes, were based on the medical documents signed by the ---6 7 87. It gives us some idea of what the demand has Ο. been in each of those years, doesn't it? 8 9 Α. Well as I said, we have not seen or been made aware of any study that actually links the level of 10 the authorizations to the level of actual consumption by 11 12 patients for medical purposes. 88. Q. So I take it, you're -- well, we'll go to 13 14 the Affidavit. Let's just, while we're at this 15 Affidavit, if you then go past the letter from the international drug people to the next Freedom of 16 17 Information Request, you should be right in sequence. 18 It's a document dated December 16th, 2013. 19 Α. Yes. 20 89. Q. Another Freedom of Information Request 21 basically asking, and I'll put it to you, 22 "At the time of the repeal of licenses issued 23 under the MMAR on March 31, 2014, based on the 24 actual applications received by Health Canada as 25 well as the licenses Health Canada anticipates

to issue for production of cannabis, the anticipated total annual production capacity of dried cannabis expressed in kilograms per year of all anticipated license producers under the MMAR estimated to be as of April 1st, 2014. Would you be kind enough to provide us with your estimate in this regard on a monthly basis commencing August, 2013 and ongoing to March, 2014?" If you go to the next page, there is a reporting dashboard. Do you see that? I do, yeah. Α. 90. If you go to the page following that, Q. there's a figure, "As of October 2nd, 2013 current risk weighted

production forecast, 3,055 kilograms in April of 2014."

17 Is that correct?

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

25

18 A. Correct.
19 91. Q. Is that -- do you agree with that figure?
20 A. Do I agree with it now? No.

92. Q. Yeah. What do you say it is now?
A. Well it's the figure that's provided in the
Affidavit in paragraph --Q. Which figure is that?

24 93. Q. Which figure is that?

A. Paragraph 29.

Q. Eight hundred and fifty kilograms. So,
 you're saying that as of April, 2014 there will only be
 850 kilograms available?

4

5

6

7

8

9

10

11

12

95.

A. No. As the Affidavit states, that is what licensed producers have indicated to us they will be producing in April. The total amount available will be that amount plus the accumulated inventory leading into the month of April. As I said already, producers to date have accumulated 100 kilograms.

Q. All right. So the accumulated inventory. That's what you're talking about, is the 100 kilograms?

A. So far, that's right.

13 96. Q. Okay. That, you're saying, will be available 14 for acquisition by patients on April 1st, 2014. Is that 15 right?

So, what will be available in April will be 16 Α. the amount produced in the month itself as well as the 17 18 available inventory from the licensed producers coming into the month. The amount we are aware of today is an 19 20 accumulated inventory of 100 kilos. What that number 21 will precisely be on April 1st or March 31st, we don't have the exact number, but the projection is, is that 22 23 the licensed producers will continue to accumulate 24 inventory leading into the month of April.

25 97. Q. So, you're calculations to determine whether

or not there will be enough available for patients come 1 April 1st, I take it you agree there's no relationship 2 3 to what was authorized in these prior years? You've calculated on a totally different basis as to what will 4 5 be -- what the demand will be. Is that correct? There are quite a number of factors that 6 Α. 7 we've looked at. The biggest one is the number of patients as well as what the consumption patterns will 8 9 be moving forward. There's four key data points that I 10 would point to in thinking about what consumption will be on a go forward basis. What we've seen 11 12 internationally in countries that have national programs of scale in Israel and in The Netherlands, those numbers 13 are cited I believe in some of the documentation 14 15 provided. The Dutch program has a daily consumption on average of less than a gram -- actually, less than 0.7 16 17 of a gram a day. The Israeli program has consumption of about a gram and a half a day. Our own experience in 18 supplying patients in the MMAR, the older regulations, 19 20 on average those patients consumed 1.2 grams per day. 21 Under the new regulations, the licensed producers that we've been discussing, they've registered almost 1000 22 23 patients and made almost 1000 shipments. The average shipment is a gram a day. So, we're seeing a fairly 24 25 consistent pattern of what consumption will start to

1

2

3

4

5

6

7

8

9

10

11

24

25

look like under the new regulatory regime. So that was a very important consideration and remains one that we're monitoring closely as we move into the new regulatory regime.

98. Q. So, if I'm understanding you, you're saying that rather than do the calculations based on, for example the figures we looked at in the Freedom of Information Requests as to grams per day authorized in Canada, instead of relying on those figures you rely on figures from The Netherlands and Israel indicating 1.5 grams per day as being the standard. Is that correct?

Well in addition, the figure we have from 12 Α. our own experience in supplying patients. We've been 13 14 supplying patients under the MMAR for almost eight years 15 and we have production records, we have sales records based on the thousands of patients that we've supplied 16 17 over that extended period of time. The average 18 consumption that we've seen from patients in that circumstance was as I said, about 1.2 grams per day. 19 20 Under the new program with, as I said, just under 1000 21 patients registered, just under 1000 shipments made to date, the average shipment has been a gram a day. 22 23 99. I'm sorry, I'm not -- I don't know if I'm Q.

9. Q. I'm sorry, I'm not -- I don't know if I'm understanding you. You say shipments to date, are you talking about shipments by the licensed producers?

A. Correct. 1 2 100. So can you give me that again? How much can Ο. 3 the licensed producers supply or have they supplied to date -- sold to date? 4 5 Α. The total amount in kilos that they've 6 supplied to date, I do not have that number. I do know 7 that they have made under -- just under 1000 shipments to date as of -- sorry, as of January 30th. 8 9 101. Q. I see. 10 A. And that the average shipment is right around a gram a day. 11 Q. Are you able to break down which of the 12 102. licensed producers was able to do that? 13 Well, as of January 30th, I believe there 14 Α. 15 were four of the licensed producers that are mentioned 16 in paragraph 26 who have actually made shipments to 17 clients. 18 103. Q. Can you identify which ones those are? 19 That have made shipments as of January 30th, Α. 20 CanniMed, Mettrum and Peace Naturals for sure. From 21 memory, I am -- maybe just those three who've made 22 shipments as of that date. 23 104. Q. So Mettrum has been able to actually sell 24 some product to the public. Is that what you're saying? 25 Α. Yes.

105. In order to do that it obviously has to pass 1 Q. 2 all of the tests and everything, correct? 3 A. Correct. 106. Q. Okay. See, I'm told that Tweed for example, 4 5 that is supposed to have your biggest production 6 capacity only has about 1,700 square feet production 7 available now and is planning to have about 150,000 square feet in the future. Do you know whether that's 8 9 accurate or not? The estimates that are contained in 10 Α. paragraph 29 are based on discussions with the licensed 11 12 producers about where they think they will be on production as of April. 13 Q. So we don't have an actual timeline, say 14 107. 15 from Tweed, do we? They have given us an indication of how they 16 Α. 17 will ramp up their production, yes. 18 108. What's that? How will they do that? Q. 19 I'm sorry, can you re-ask the question? Α. 20 109. Q. How will they ramp up their production for 21 April 1st? 22 Α. They have a large number of plants already 23 under cultivation. They've been licensed for the 24 footprint they need to make the production numbers that 25 they have already provided to us and are included in

these estimates. 1 2 110. But they haven't sold any product yet, have Ο. 3 they? That is not my understanding -- my 4 Α. 5 understanding is that they have not yet sold a product, 6 but they have begun to register patients. 7 111. Q. Your understanding though is that Mettrum has been able to sell product, so if you recall, I've 8 9 been told that they were having trouble passing 10 biological tests. But that's not your understanding. Your understanding is that they have actually been 11 12 authorized to sell product and have in fact sold product. Is that right? Mettrum. 13 A. Correct, yes. 14 15 112. Q. What about CanniMed? Let me just clarify, CanniMed is a wholly own subsidiary of Prairie Plant, 16 17 correct? 18 I'm not sure of the nature of which is the Α. parent and which is the subsidiary, but they are owned -19 20 ___ 21 113. O. Related? 22 Α. --- they are the same company, yes. 23 114. Yeah, okay. Now, at paragraph 33 you refer Q. 24 to arrangements with Prairie Plant to purchase overstock 25 as a reserve in case of a supply short fall during the

transition period and you say that Health Canada secured 1 2 four to five hundred kilograms of dried marijuana available for sale now to Canadians and that you haven't 3 had to rely on it. So is this the Prairie Plant System 4 5 product that according to statistics approximately 20 6 percent of the patients were accessing or to access? 7 That's the ---Α. 115. Is that the old Prairie Plant product? 8 Q. 9 That is right. Α. The stuff that wasn't very popular with the 10 116. Q. 11 patients? 12 It is the product that we purchased under Α. contract to meet the needs of patients under the 13 Marijuana Medical Access Regulations. 14 15 117. Q. But it's the same product that was, 16 according to some of the material, not very popular 17 amongst the patients. They didn't like, they had some 18 complaints about it. It's that same product? 19 It's the strain they've been producing for Α.

20 years.
21 118. Q. Okay. So, it's a particular strain? It's not
22 any of the new strains or anything that they have been
23 producing as CanniMed?
24 A. That's right.

119. Q. Okay. Bedrocan is the import from The

Netherlands, correct? 1 2 A. Yes. 3 120. Q. Did you know that its product was similarly unpopular in The Netherlands? 4 5 A. I'm aware of the sales figures under the 6 Dutch program but not of any kind of qualitative 7 assessment of the Bedrocan product in The Netherlands. 121. Q. You weren't aware -- you've been told about 8 9 patient not liking their product or any of that information was not -- you weren't aware of that? 10 A. No. 11 Q. You're shaking -- okay. Peace Naturals, I'm 12 122. 13 told has 800 patient registered and is not taking any more at the moment. Did you know that? 14 15 A. I know that they are close to the production capacity. I don't know the specific numbers of how many 16 17 patients they have registered to date. 18 123. Q. Well, I'm told that they aren't taking any 19 new ones because they're at their current production 20 capacity which is 800. You're unaware of that? 21 I don't recall the specific numbers of Α. 22 registrations with Peace Naturals. 23 124. Q. Well, are you able to give us the production 24 capacity for each one of those that are ready to go at 25 this point besides the 850 estimate? Can you give us

anything more specific for each one currently? 1 2 I don't have those numbers here with me, but Α. these calculations are based on the summation of the 3 individual company production estimates. 4 5 125. Q. Is what you're being told, what the 6 companies are hoping they will be able to do as opposed 7 to what we know they have in fact done to date. Fair enough? 8 9 A. Yes. 10 126. Q. Are you able to tell us how many patients have registered with the licensed producers? Each one of 11 12 them. So the figure I cited earlier of just under 13 Α. 1000 is the collective total for the licensed producers 14 15 to date. But yes, that's based on individual numbers from those licensed producers. I do not ---16 17 127. Q. If I understand that ---18 --- have those figures. Α. 19 128. Q. Sorry? 20 Α. I don't have the breakdown of the just under 21 1000 patients by the licensed producers but it's based 22 on the total provided -- total of the individuals 23 registrations of the six licensed to date. So, roughly 1000 patients total registered 24 129. 0. 25 so far. Is that right?

CATANA REPORTING SERVICES, 800-170 Laurier Ave. W., Ottawa, ON K1P 5V5 Tel: (613) 231-4664 1-800-893-6272 Fax: (613) 231-4605 That's right. 1 Α. 2 130. Under the MMPR? Ο. 3 As of January 30th, yeah. Α. 131. As of January 30th. You don't have any 4 Q. 5 updates since then? 6 Α. No. 7 132. Q. So if we're looking at your Affidavit and the paragraphs 26 through 29, you indicate 31,000 --8 9 projected annual production of 31,000 kilograms in 10 paragraph 27, correct? 11 A. Yes. You predicted another 12 will be licensed by 12 133. Q. 13 March 31st. Is that still the case? 14 A. It is. 15 134. Q. You say that with the additional 12, that 16 that will increase it by 31,000 to 45,000, correct? 17 A. Correct, an addition 14,000 kilos to take us 18 to a total of 45,000. 19 135. Q. Okay. So, if we -- you add to that, as I 20 understand it, this 400 to 500 kilos that's the 21 shortfall that's at paragraph 33 to come up with a total 22 available? 23 A. No, the paragraph -- if you are referring to 24 paragraph 29, that is based on the production forecast 25 of the licensed producers it does not include ---

136. Q. Six of them. At paragraph 28, you talk about 1 2 licensed producer's websites and what's available and so 3 on. If you've got your Affidavit in front of you, let's qo to those websites. Just before we do, you say 60 4 5 strains available at prices \$5.00 to \$12.00 offering 6 discounts -- you say licensed producers, plural, 7 offering discounts as low as \$3.00 a gram for low income users. My understanding is that it -- was Peace Naturals 8 9 that was offering that \$3.00 a gram? 10 Α. Peace Naturals has a discount program that will go as low as \$3.00. Tweed also has a discount 11 program. It's in the website. I believe it's 20 percent 12 off of their lowest price strain which would take us to 13 around the \$4.00 or the -- just below \$4.00 a gram 14 15 range. 137. Q. So we have -- we don't have anybody able to 16 supply under \$4.00 -- well, under \$3.00 a gram, do we? 17 18 A. Not that I'm aware of. 138. See I'm told that the Plaintiffs indicate 19 Ο. 20 that they've been able to produce -- they've learned how 21 to produce because they couldn't afford black market prices so they've learned how to produce it between 22 23 \$0.50 and \$4.00 a gram. So there aren't any licensed producers able to supply those patients who are 24 25 accessing it between \$0.50 and \$3.00, are there?

MR. BRONGERS: Mr. Conroy, so the question is, is the witness aware of any producers or selling the product for between \$0.50 and \$3.00 a gram. Is that the

BY MR. CONROY:

Q. Well, are they able to supply people at that
amount? There aren't any that are able to supply people
at that amount, are there?

A. Well at that ----

10 140. Q. At that price?

question?

1

2

3

4

5

9

11

12

A. The pricing that's available on the market is what's reflected in the appendix or the Exhibit.

13 141. Q. But the point is, is that those people who 14 say they can't afford those prices, there isn't any 15 provision made for them anywhere is there? Other than 16 the two items we talked about, Peace going down to 17 \$3.00. I think with Peace, it's \$3.00 if you're on the 18 disability pension, correct?

MR. BRONGERS: Mr. Conroy, what concerns me is the way you're asking the question. It's in the form of an argument you're putting to the witness. If you want to ask him specifically about his knowledge of what the prices are or are anticipated to me, that's perfectly fair. But I have trouble with the preface to the question which is in the form of argument. I don't want

1		you to ask the witness and then him to agree to it and
2		make it appear that there's been some sort of a
3		concession on the Record that your legal argument is
4		founded. So, if we could confine the questions to facts
5		instead of argument it would be appreciated.
6		BY MR. CONROY:
7	142.	Q. All right. Well, your evidence sir is that
8		Peace Naturals is offering at $\$3.00$ a gram and it's
9		is it only for people on disability pensions or is it to
10		all potential patients or do you know?
11		A. The information I'm aware of is what's
12		reflected in the Exhibit.
13	143.	Q. All right. Well, let's go to your Exhibits
14		then. Start with the web pages. The first one is
15		Bedrocan, do you have that? It's offering patients at a
16		flat rate of \$7.50 per gram including shipping, correct?
17		A. Yes.
18	144.	Q. That's on the first page. Bedrocan, because
19		it's coming from The Netherlands in that 100 kilogram
20		amount, that's available now. Is that right?
21		A. They have inventory available for sale now,
22		yes.
23	145.	Q. The patients could start registering and
24		purchasing from Bedrocan at \$7.50 a gram as indicated
25		now?

0

		A REPORTING SERVICES, 800-170 Laurier Ave. W., Ottawa,ON K1P 5V5) 231-4664 1-800-893-6272 Fax: (613) 231-4605
1		A. That is my understanding, yes.
2	146.	Q. To your knowledge, at no lesser amount than
3		\$7.50 a gram, correct?
4		A. Correct.
5	147.	Q. They indicate at page 4 of 5, they're saying
6		they're taking orders starting February, 2014. You see
7		that? "Can I buy your cannabis now?" Under that heading.
8		Do you get a is it true that they've only just then
9		this month indicated they're ready to sell?
10		A. That it my understanding, yes. From what I
11		understand, they made their first shipment to a patient
12		late last week or early this week.
13	148.	Q. All right. Then if we go to the next one
14		is Canna Farms and it's here in BC, correct?
15		A. Yes.
16	149.	Q. If you go to their page 2, and it goes right
17		through from page 2 to page 5, none of their product is
18		available until
19		A. Mid April.
20	150.	Q well one Mid April is one but most of
21		it's May 30th, May 15th and May 30th as I glance through
22		them. Isn't that right?
23		A. Yes.
24	151.	Q. So they won't have any product available on
25		or before March the 1st then?

		A REPORTING SER) 231-4664	VICES, 800-170 Laurier Ave. W., Ottawa,ON K1P 5V5 1-800-893-6272 Fax: (613) 231-4605
1		А. Т	hat's my understanding.
2	152.	Q. 0	kay. Then I don't know if we have a
3		price? Canna	Farms doesn't give us a price do they?
4		A. I	hey don't.
5	153.	Q. D	o you know what their price range is?
6		A. I	don't have specific knowledge of Canna
7		Farms pricing	
8	154.	Q. 0	kay. The next one is CanniMed and this is
9		the Prairie P	lant related company, correct?
10		A. C	orrect.
11	155.	Q. I	f we go to their flip to page 3, their
12		price indicat	es 10 and 30 sorry, product prices range
13		from \$7.50 tc	\$12.00 a gram, top of page three, right?
14		A. Y	es.
15	156.	Q. A	s far as you know that's their price and
16		there's nothi	ng lower than that, correct?
17		A. W	ell on two pages on
18	157.	Q. Y	es.
19		A	they have been offering a discount
20		reflected in	the top it's page 2 of 2.
21	158.	Q. Y	eah, so there's the one for \$4.88 a gram?
22		A. C	orrect.
23	159.	Q.S	o that's their lowest price, is it?
24		А. Т	he lowest that I'm aware of, yes.
25	160.	Q. G	o back to page 3 where the first prices

1		were set out. It references Veteran Affairs Canada		
2	giving continued coverage. You see that?			
3		A. Yes.		
4	161.	Q. As I understand it, that means that veterans		
5		who qualify will be able to have their cost of their		
6		medicine covered under that program. Is that right?		
7		A. I don't know all of the details of the		
8		Veterans Affairs Program, but there are a small number		
9		of veterans who have had reimbursement for medical		
10		cannabis.		
11	162.	Q. There are no other programs like that in		
12		Canada for any others at this time, are there?		
13		A. I've been informed that there may be some		
14		Provincial Workers Compensation, Workers Safety and		
15		Insurance Board plans that have offered some level of		
16		coverage but I don't have any more specific knowledge of		
17		the details of what that is.		
18	163.	Q. Provincial Workers Compensation Plans, any		
19		particular provinces?		
20		A. I don't know the specific provinces where		
21		they have coverage.		
22	164.	Q. All right. The next web page then is Mettrum		
23		and their prices this page doesn't seem to have page		
24		numbers. The third page in has some prices, \$7.60 per		
25		gram. Do you see that?		

K1P 5V5 CATANA REPORTING SERVICES, 800-170 Laurier Ave. W., Ottawa, ON Tel: (613) 231-4664 1-800-893-6272 Fax: (613) 231-4605 Yes, I do. Mettrum Red. 1 Α. 2 165. They don't -- sorry? Ο. 3 Α. Where it says ---166. They don't need to ---4 Q. 5 Α. That's okay. Sorry, I just wanted to confirm 6 that you were referring to the entry under Mettrum Red 7 number one and then price ---167. Yeah. 8 Q. 9 Yeah, okay. Α. 10 168. Q. Those are the only prices they indicate, 11 aren't they? 12 A. Correct. 13 169. No indication that they have any program to Ο. 14 sell for less than that, correct? A. None that I'm aware of. 15 16 170. The next one then is Peace Naturals. The Q. 17 first page of their web page indicates their medicine 18 will cost \$6.00 a gram and a minimum order of 15 grams. 19 You see that? 20 A. I do. 21 171. Q. They discuss the medical plan issue at the 22 next page and again, refer to the Veteran's Affairs and 23 then the income tax aspect, correct? 24 A. Correct. 25 172. Q. Then if we -- there's no other, at least in

these documents, indication of this \$3.00 offer. Does that appear anywhere or am ---

1

2

3

4

5

6

10

11

12

13

A. No, it's not included in these documents. There is a reference to compassionate pricing on their website though not on one of these pages that's been reproduced.

7 173. Q. What's your understanding of the
8 compassionate pricing? Is it essentially providing it to
9 the patients at less than their cost?

A. I'm not aware of whether it's related to their cost structure. But it is a program where they have established some conditions on which they'll offer this discounted cost per gram.

14 174. Q. Okay. Then Tweed is the next one. At page 4 15 of 5 indicates under \$5.00 per gram. Do we have any 16 other information as to how much under or anything like 17 that?

18 So they've indicated on their website that Α. 19 they will have pricing between \$5.00 and \$12.00 a gram 20 and they've committed to a certain percentage of production being under \$5.00 a gram. And then ---21 22 175. If we go to further on their ---Q. 23 --- Compassionate program. Α. 24 176. --- page 1 of 3 I think is the -- that's the Ο. 25 compassionate program?

800-170 Laurier Ave. W., Ottawa, ON CATANA REPORTING SERVICES. K1P 5V5 Tel: (613) 231-4664 1-800-893-6272 Fax: (613) 231-4605 A. Correct. 1 2 177. So then they indicate 10 percent of their Q. 3 product will be 5 grams of less including shipping. Fair enough? 4 5 Α. Yes. 6 178. Then they say, 20 percent discount and if I Q. 7 understand it correctly, upon proof of being in a Federal or Provincial Program such as a pension program. 8 9 Fair enough? 10 Α. That is my understanding as well. 179. So anybody with an income under \$29,000 per 11 Q. 12 year would appear to qualify for that program? Well as the conditions indicate on the web 13 Α. 14 page, they have two conditions for eligibility. 15 180. Q. I'm looking at the next page following that and I'm wondering -- at page 2 of 3, British Columbia 16 17 appears, but is there something blocked out by that 18 Tweed banner in the next -- that relates to British Columbia or is it just ---19 20 A. I believe there is. There's some text, some 21 additional provincial programs that are covered up by 22 the banner of the webpage just did not render properly 23 when it was printed. 24 181. Then the last one that I have is just a one Ο. 25 page Delta nine Bio-tech?

		A REPORTING SERVICES, 800-170 Laurier Ave. W., Ottawa,ON K1P 5V5 b) 231-4664 1-800-893-6272 Fax: (613) 231-4605
1		A. Yes.
2	182.	Q. Can you tell us anything about them in terms
3		of pricing?
4		A. I can't as of yet. They're one of the
5		companies that have had this graduated license to begin
6		production as they finish out the rest of their
7		facility. But they have not as yet, to my knowledge,
8		established their pricing.
9	183.	Q. So do you have any additional information,
10		any update since you've filed this Affidavit in relation
11		to these or any other of the licensed producers as far
12		as pricing
13		A. I don't.
14	184.	Q and discounts?
15		A. No.
16	185.	Q. But that pertinent information remains
17		what's here in your affidavit essentially?
18		A. Yes.
19	186.	Q. Okay. So if I understand the plan for
20		transition that is indicated at paragraph 30 and over on
21		31, you're basically saying that based on the literature
22		from The Netherlands and Israel in terms of the usual
23		consumption in grams per day and Health Canada as
24		indicated at the end of 31, you took those grams per day
25		figures and using those gram per day figures, made the
	1	

calculations to determine what the demand would be on an 1 2 annual basis. Is that right? 3 Α. That's one approach that we've used, yes. 187. You agree though that those gram per day 4 Q. 5 amounts appear to be substantially less than what was actually authorized in Canada under the MMAR as 6 7 indicated in that earlier Freedom of Information document we looked at. Fair enough? Grams per day I 8 9 should ---These are the number that are available that 10 Α. 11 show actual consumption as opposed to those other numbers which are authorizations. 12 188. So when you say, actual consumption, the 13 Ο. 14 Health Canada actual consumption figure -- do we have 15 that? The indication is 1.5 is Israel, correct? 16 A. Correct. 17 189. Point six eight is The Netherlands, correct? Q. 18 A. Correct. 19 190. Where is Health Canada's? Q. 20 Α. It's not included in the Affidavit, but that 21 figure based on our analysis of the book -- the 22 purchasing records from our Health Canada clients under 23 the MMAR is that 1.2 grams per day was the average 24 purchase. 25 191. Q. The average purchase. Well, are you able to

tell us that there will definitely be enough product 1 available for all registered -- by registered patients 2 in Canada on April 1st, 2014, you would treat the 3 registered patients as currently 1000? Is that right? 4 5 MR. BRONGERS: Mr. Conroy, again, I'm concerned 6 with the preface to the question. If we could just focus 7 on facts that might be within the knowledge of the witness. You're asking him to definitely guarantee 8 9 something that will happen in the future. I think that's 10 unreasonable to ask anybody. But if we could just ask him about his understanding of what the situation is 11 12 likely to be then that of course is fair game. BY MR. CONROY: 13 14 192. Q. Well you see, going back to your paragraph 15 13, you indicate that you're the person presently charged with developing and implementing the strategy 16 17 and ordered to try and make sure that there is going to 18 be enough product in place so that the patients will be able to get it on April 1st, correct? 19 20 Α. Yes. 21 193. So you then indicated sub E that you've Q. 22 devised a contingency plan in the event that there isn't 23 going to be enough, correct? 24 Correct. Α. 25 194. Q. So are we into the contingency plan or not?

47

0

A. We are not into the contingency plan. 1 2 195. So your view remains that you think there's Ο. going to be enough product available come April 1st 3 without having to resort to the contingency plan. Is 4 5 that right? 6 A. Correct. 7 196. That's based though on the 1 to 3 or 1 to Q. 1.5 gram a day consumption data, correct? 8 9 In part. The other considerations are Α. 10 obviously the production levels, the conversion of patients under the old program to the new, the growth 11 rate of new patients coming in to either the old program 12 or the new program. There are quite a number of 13 variables that will drive what actually happens on the 14 15 ground after April 1st. 16 197. Q. Because 1000 registered patients is 17 substantially less than the number of people who have 18 been applying under then MMAR over the last year. Isn't that right? We're up to something like 38,000 applicant 19 20 or patients now? 21 The number of authorizations to possess to Α. 22 the best of my knowledge is around 38,000 under the old

24 198. Q. So, 38,000 approximately under the old, or a
25 program that continues until March 31st, but only 1000

program guidelines, yes.

registered under the new program. Is that right? 1 2 As of January 30th. Α. 3 So your projections are simply limited to 199. Q. the 1000 and that they'll be enough produced for people 4 5 who've registered? 6 Α. No. 7 200. That's your position? Q. No. No, obviously we have looked at the 8 Α. 9 38,000 and how they will convert over to the new program 10 after April 1st. Within the 1000 patients that have registered under the new program so far, there is a mix 11 12 of people who have obtained the new medical document and a number who have an authorization to possess and have 13 14 chosen to convert over to the new method of supply 15 before March 31st. I don't have the exact breakdown of those, but hundreds of the patients who have registered 16 to date under the MMPR with our licensed producers are 17 18 people who have come over from the regulation which will be repealed on March 31st. 19 20 201. Q. But there's only 1000 of them. Is that 21 right? 22 Α. So far, yes. 23 202. We know there were as many as 38,000 that Q. 24 have authorization to possess? 25 Α. Yes.

CATANA REPORTING SERVICES, 800-170 Laurier Ave. W., Ottawa,ON K1P 5V5 Tel: (613) 231-4664 1-800-893-6272 Fax: (613) 231-4605

203. Q. And personal production -- I think the 1 2 personal production figure was about 25,000 or 26,000. 3 Is that right? We have the actual figures somewhere ---Yeah, they're in the documents. 4 Α. 5 204. Ο. --- it appears that a lot of people who are 6 registered under the MMAR with authorizations to possess 7 and personal production licenses have not registered under the MMPR. Is that right? 8 9 Α. Correct. 205. 10 Q. To date. 11 To date. Α. There's only 40 days, roughly, to go. Fair 12 206. Q. 13 enough? 14 Α. Yes. 15 MR. BRONGERS: Mr. Conroy, just in terms of time management, I see it's now 10:30 and as you know, we 16 17 have to complete this by 1:00PM. I'm just wondering in 18 terms of timing. You have another witness to examine and 19 I think people here might be ready for a break. I don't 20 want to interrupt up you in mid-stream, but maybe we 21 should plan some timing here in terms of when we stop 22 for a short break. 23 MR. CONROY: Okay. 24 BY MR. CONROY: 25 207. Q. So, even if we took 3 grams a day as the

dosage standard, I put to you that they will not be able to produce enough for 40,000 patients if they all register by March 31st. Would you agree?

MR. BRONGERS: Mr. Conroy, I'm having trouble understanding the question. So instead of using the 1 gram figure, you want to make the calculation based on a 3 gram figure. Is that the hypothesis?

MR. CONROY: Well, no. What's I'm getting at I guess is this, if we've got 38,000 patients under the MMAR and if they were all at 3 grams per day and you multiplied that by 365 for the year and you divide that by the 1000 you get 40,000 kilograms a year, don't you?

MR. BRONGERS: Are you asking the witness to do some math? I don't understand.

BY MR. CONROY:

16 2

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

17

18

19

20

21

22

23

24

25

208. Q. Well, I'm asking him -- you see I'm saying, wouldn't that be the amount that would be -- have to be available for 40,000 people?

A. There's a number of assumptions built into that particular calculation. Historically, what we've seen with authorizations to possess, particularly for those who said that Health Canada was going to be their source of supply, many of them never placed an order under the program even those they had the proper documentation to do so. A number of them placed a one-

time order and then never placed a second order. As you 1 may be aware, a number of patients would get an 2 3 authorization to possess and wouldn't be clear on what basis they were managing their supply. So, it's a big 4 5 assumption to say that all 38,000 patients will 6 immediately convert over to the new method of supply 7 because they weren't obviously served by one of the old methods of supply under the MMAR. Then as I've said 8 9 repeatedly, the trend that we're seeing for actually 10 purchasing, actual consumption under conditions more like this MMPR mode of supply seems to line up around 11 12 that gram per day figure. 209. Q. At paragraph 36 you talk about a possibility 13

. Q. At paragraph 36 you talk about a possibility of a collaborative approach. Has that gone any further?

A. Not as of yet.

14

15

23

24

25

16 210. At paragraph 37 you say that Health Canada Q. 17 has made a significant effort to provide reasonable 18 access and will continue to monitor supply and demand for this purpose. So, I take it you agree that you can't 19 20 be sure at this point that there's going to be enough 21 supply for the patients come April 1st, 2014. Is that 22 fair?

A. That's correct. This is an unprecedented system to transition over to so there are any number of things that could change that would result in either a

2

11

12

13

14

significant surplus or possibly some level of supply gap.

3 211. Q. In paragraph 39 you talk about the principle that a legal supply of dried marijuana for medical 4 5 purposes must be reasonably accessible, that a market of 6 dried marijuana purchases must exist to support the 7 newly licensed producers industry. Would you agree with me that your role and focus has been to try and ensure 8 9 that this market is created and supported? That's your 10 focus?

A. It has been to try and support licensed producers in achieving licensure and being able to start up their production to serve the legal needs of patients for medical cannabis.

15 212. Q. So you didn't look at all at the problem of 16 those who will not be able to afford the licensed 17 producers prices, did you?

18 MR. BRONGERS: Mr. Conroy, so you're asking Mr. Cain in terms of his individual capacity whether that 19 20 was his task or are you asking -- because the paragraph 21 refers to Health Canada's approach. So that's why I'm a bit confused with what -- are you asking ---22 23 BY MR. CONROY: 24 213. He was assigned certain tasks, so I'm asking Ο.

if that was included in part of his tasks to look at

25

also those people who won't be able to afford these licensed producers prices.

A. It was not specifically one of the tasks that I was given. It's been the subject of a number of discussions with licensed producers and prospective licensed producers and in part, the results that we've seen with Tweed and with Peace Naturals, those are a result of discussions around serving the needs of some segments of the patient population who may have additional challenges under the program.

11 214. Q. Is there documentation that is made 12 available by the LPs on a regular basis that would be 13 able to update people as to the production availability 14 as we approach April 1st?

A. As a regular ---

16 215.

15

1

2

3

4

5

6

7

8

9

10

Q. Documents from them?

A. As a regulated party, condition of licenses
is that they provide us with regular information so that
we can conduct ourselves around the compliance and
enforcement of the regulations.

21 216. Q. So there is documentation that could be made 22 available to the court to show the current status of 23 production and so on that say as of March 18th, 2014? 24 MR. BRONGERS: Again, I'm concerned with the way 25 that you asked the question, Mr. Conroy, and the assumption that there will be more evidence perhaps presented to the court prior to the hearing of our Motion. I think it is perfectly fair to ask whether more documents will be coming from these licensed producers, but I'm going to object if the question is asked in terms of will we be providing more material to the court.

8

1

2

3

4

5

6

7

10

11

12

13

14

15

16

17

18

19

BY MR. CONROY:

9 2

Q. I didn't ask if you'd be providing it. I'm asking if it's available. Is that information available? I think the witness said that they do have to file with you regular updates. That's what I'm get -- are regular updates provided so that you have an indication of exactly what the situation will be as far as availability of product, March 18th for example?

A. So regular updates are -- regular reports are filed by the licensed producers as per the conditions of their license. Those are typically provided at the end of each calendar month.

20 218. Q. So, if there's a problem in terms of a 21 production amount, as of April 1st, is that then when 22 this Prairie Plant overstock kicks in? Paragraph 33. Or 23 is that taken into account already? 24 Could you clarify the question for me? Α. I was trying to determine if we're going to 25 219. Q.

have -- be able to get current information right up to 1 April 1st in terms of what's available from the licensed 2 3 producers. If there's a shortfall, the plan then is to use the Prairie Plant product as indicated in paragraph 4 5 33 to make up the difference? To try and make up the 6 difference? 7 A. So that is -- it is a possibility that that 8 could be made available if some sort of a supply gap 9 does emerge. 10 220. Q. All right. Subject to -- well, let's go off the Record for a minute. 11 12 (OFF RECORD DISCUSSION) 13 MR. CONROY: Those are all the questions I have 14 for Mr. Cain, thank you. 15 THE WITNESS: Thank you. --- WHEREUPON THE EXAMINATION ADJOURNED AT THE HOUR OF 16 17 1:42 IN THE AFTERNOON. 18 THIS IS TO CERTIFY THAT the foregoing is a 19 20 true and accurate transcription from the 21 Record made by sound recording apparatus to the best of my skill and ability. 22 23 24 25 Leigh Gordon, Court Reporter